Congenital adrenal hyperplasia
Conditions
Brief summary
Closure of urogenital sinus (Prader stage), Gestational weight gain (GWG) of mother
Detailed description
Parameters of treatment consequences/safety in treated mothers and children, safety parameters: stillbirths, miscarriages, maternal side effects and adverse events, serious adverse events (AEs, SAEs) in treated mothers and children, maternal quality of life, maternal mental health and sleep, child´s birth weight and height at birth, week of gestation at birth, infant nervous system development, malformations in the child)
Interventions
DRUGDexamethason 0.21mg
DRUGDexamethason 0.15mg
DRUGDexamethason 0.41mg
DRUGDexamethason 0.5mg
Sponsors
Philipps-Universitaet Marburg
Eligibility
Sex/Gender
All
Age
0 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Closure of urogenital sinus (Prader stage), Gestational weight gain (GWG) of mother | — |
Secondary
| Measure | Time frame |
|---|---|
| Parameters of treatment consequences/safety in treated mothers and children, safety parameters: stillbirths, miscarriages, maternal side effects and adverse events, serious adverse events (AEs, SAEs) in treated mothers and children, maternal quality of life, maternal mental health and sleep, child´s birth weight and height at birth, week of gestation at birth, infant nervous system development, malformations in the child) | — |
Countries
Germany
Outcome results
None listed